185 related articles for article (PubMed ID: 8879230)
41. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.
Brandt SJ; Bodine DM; Dunbar CE; Nienhuis AW
J Clin Invest; 1990 Aug; 86(2):592-9. PubMed ID: 2384605
[TBL] [Abstract][Full Text] [Related]
42. Mixed connective tissue disease associated with multicentric Castleman's disease.
Nanki T; Tomiyama J; Arai S
Scand J Rheumatol; 1994; 23(4):215-7. PubMed ID: 8091149
[TBL] [Abstract][Full Text] [Related]
43. The kappa B enhancer of the human interleukin-6 promoter is necessary and sufficient to confer an IL-1 beta and TNF-alpha response in transfected human cell lines: requirement for members of the C/EBP family for activity.
Merola M; Blanchard B; Tovey MG
J Interferon Cytokine Res; 1996 Oct; 16(10):783-98. PubMed ID: 8910763
[TBL] [Abstract][Full Text] [Related]
44. Redundancy of C/EBP alpha, -beta, and -delta in supporting the lipopolysaccharide-induced transcription of IL-6 and monocyte chemoattractant protein-1.
Hu HM; Baer M; Williams SC; Johnson PF; Schwartz RC
J Immunol; 1998 Mar; 160(5):2334-42. PubMed ID: 9498774
[TBL] [Abstract][Full Text] [Related]
45. Multicentric Castleman's disease: imaging findings.
Feldman DR; Schabel SI
South Med J; 1996 Dec; 89(12):1159-61. PubMed ID: 8969348
[TBL] [Abstract][Full Text] [Related]
46. Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.
Ikeda S; Chisuwa H; Kawasaki S; Ozawa J; Hoshii Y; Yokota T; Aoi T
J Clin Pathol; 1997 Nov; 50(11):965-7. PubMed ID: 9462253
[TBL] [Abstract][Full Text] [Related]
47. Castleman's disease.
Palestro G; Turrini F; Pagano M; Chiusa L
Adv Clin Path; 1999; 3(1-2):11-22. PubMed ID: 10655569
[TBL] [Abstract][Full Text] [Related]
48. Multicentric Castleman's disease in a child with prominent thymic involvement: a case report and brief review of the literature.
O'Reilly PE; Joshi VV; Holbrook CT; Weisenburger DD
Mod Pathol; 1993 Nov; 6(6):776-80. PubMed ID: 8302822
[TBL] [Abstract][Full Text] [Related]
49. Limited expression of C/EBP family proteins during B lymphocyte development. Negative regulator Ig/EBP predominates early and activator NF-IL-6 is induced later.
Cooper CL; Berrier AL; Roman C; Calame KL
J Immunol; 1994 Dec; 153(11):5049-58. PubMed ID: 7963564
[TBL] [Abstract][Full Text] [Related]
50. An immunohistological and genotypic study of the plasma cell form of Castleman's disease.
Hall PA; Donaghy M; Cotter FE; Stansfeld AG; Levison DA
Histopathology; 1989 Apr; 14(4):333-46; discussion 429-32. PubMed ID: 2737612
[TBL] [Abstract][Full Text] [Related]
51. Intestinal lymphangiectasia associated with angiofollicular lymph node hyperplasia (Castleman's disease).
Moss SF; Thomas DM; Mulnier C; McGill IG; Hodgson HJ
Gut; 1992 Jan; 33(1):135-7. PubMed ID: 1740268
[TBL] [Abstract][Full Text] [Related]
52. [Angiofollicular lymphatic hyperplasia with plasmacytoma and polyneuropathy: a case report with immunohistochemical study].
Dworák O; Tschubel K; Zhou H; Meybehm M
Klin Wochenschr; 1988 Jul; 66(13):591-5. PubMed ID: 3210655
[TBL] [Abstract][Full Text] [Related]
53. Cutaneous multicentric Castleman's disease mimicking IgG4-related disease.
Takeuchi M; Sato Y; Takata K; Kobayashi K; Ohno K; Iwaki N; Orita Y; Yoshino T
Pathol Res Pract; 2012 Dec; 208(12):746-9. PubMed ID: 23102767
[TBL] [Abstract][Full Text] [Related]
54. Immunodeficiency and IL-6 production by peripheral blood monocytes in multicentric Castleman's disease.
Ishiyama T; Nakamura S; Akimoto Y; Koike M; Tomoyasu S; Tsuruoka N; Murata Y; Sato T; Wakabayashi Y; Chiba S
Br J Haematol; 1994 Mar; 86(3):483-9. PubMed ID: 8043430
[TBL] [Abstract][Full Text] [Related]
55. Early responses of trans-activating factors to growth hormone in preadipocytes: differential regulation of CCAAT enhancer-binding protein-beta (C/EBP beta) and C/EBP delta.
Clarkson RW; Chen CM; Harrison S; Wells C; Muscat GE; Waters MJ
Mol Endocrinol; 1995 Jan; 9(1):108-20. PubMed ID: 7760844
[TBL] [Abstract][Full Text] [Related]
56. Impairment of natural killer cytotoxic activity and interferon gamma production in CCAAT/enhancer binding protein gamma-deficient mice.
Kaisho T; Tsutsui H; Tanaka T; Tsujimura T; Takeda K; Kawai T; Yoshida N; Nakanishi K; Akira S
J Exp Med; 1999 Dec; 190(11):1573-82. PubMed ID: 10587348
[TBL] [Abstract][Full Text] [Related]
57. [Large B-cell lymphoma coexisting with Castleman's disease. Report of one case].
Avilés-Salas A; Candelaria M; Sevilla-Lizcano DB; Burgos S
Rev Med Chil; 2017 Jul; 145(7):945-949. PubMed ID: 29182205
[TBL] [Abstract][Full Text] [Related]
58. Overlap of IgG4-related Disease and Multicentric Castleman's Disease in a Patient with Skin Lesions.
Mochizuki H; Kato M; Higuchi T; Koyamada R; Arai S; Okada S; Eto H
Intern Med; 2017; 56(9):1095-1099. PubMed ID: 28458319
[TBL] [Abstract][Full Text] [Related]
59. [Tocilizumab treatment of HHV8-positive/HIV-negative, multricentric plasma cell type Castleman's disease].
Mûzes G; Csomor J; Sipos F
Magy Onkol; 2016 Nov; 60(4):328-332. PubMed ID: 27898752
[TBL] [Abstract][Full Text] [Related]
60. Castleman's disease: an unusual cause of a neck mass.
Kumar BN; Jones TJ; Skinner DW
ORL J Otorhinolaryngol Relat Spec; 1997; 59(6):339-40. PubMed ID: 9364552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
